Modafinil: A review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder

CNS Drugs

Volumn 19, Issue 9, 2005, Pages 785-803

  Keating, Gillian M ^a   Raffin, Michael J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CYCLOSPORIN A; DEXAMPHETAMINE; DIAZEPAM; ETHINYLESTRADIOL; METHYLPHENIDATE; MEVINOLIN; MODAFINIL; PHENYTOIN; PROPRANOLOL DERIVATIVE; TRIAZOLAM; VERAPAMIL;

ALERTNESS; ANALYSIS; ANXIETY; BRAIN FUNCTION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG ABUSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; EPWORTH SLEEPINESS SCALE; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; INFECTION; INJURY; INSOMNIA; LOCOMOTION; MOOD; NARCOLEPSY; NAUSEA; NERVOUSNESS; NIGHT SLEEP; NONHUMAN; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHINITIS; SHIFT WORKER; SIDE EFFECT; SLEEP; SLEEP APNEA SYNDROME; SLEEP DEPRIVATION; SLEEP DISORDER; SOMNOLENCE; STEADY STATE; TOOTH DISEASE; TREATMENT OUTCOME; WAKEFULNESS; XEROSTOMIA;

ANIMALS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DISORDERS OF EXCESSIVE SOMNOLENCE; DRUG EVALUATION; HUMANS; MOTOR ACTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SLEEP APNEA, OBSTRUCTIVE; SLEEP DISORDERS, CIRCADIAN RHYTHM; TREATMENT OUTCOME; WAKEFULNESS;

EID: 24944505501     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519090-00005     Document Type: Review

References (112)

1. American Sleep Disorders Association. The international classification of sleep disorders, revised: diagnostic and coding manual. Rochester (MN): American Sleep Disorders Association, 1997
2. McClellan KJ, Spencer CM. Modafinil: a review of its pharmacology and clinical efficacy in the management of narcolepsy. CNS Drugs 1998 Apr; 9 (4): 311-24
3. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999 Jan; 39 (1): 30-40
4. Cephalon, Inc. Provigil® (modafinil) tablets: prescribing information [online]. Available from URL: http://www.cephalon.com [Accessed 2005 Aug 2]
5. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000 Nov 15; 20 (22): 8620-8
6. Engber TM, Koury EJ, Dennis SA, et al. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett 1998 Jan 30; 241 (2-3): 95-8
7. Lin J-S, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA 1996 Nov; 93: 14128-33
8. Mignot E, Nishino S, Guilleminault C, et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994; 17 (5): 436-7
9. Ferraro L, Antonelli T, Tanganelli S, et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999 Apr; 20 (4): 346-56
10. Tanganelli S, Pérez de la Mora M, Ferraro L, et al. Modafinil and cortical γ-aminobutyric acid outflow: modulation by 5-hydroxytryptamine neurotoxins. Eur J Pharmacol 1995; 273: 63-71
11. Tanganelli S, Fuxe K, Ferraro L, et al. Inhibitory effects of the psychoactive drug modafinil on γ-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea pig: possible involvement of 5-hydroxytryptamine mechanisms. Naunyn Schmiedebergs Arch Pharmacol 1992; 345: 461-5
12. 3 receptor. Neurosci Lett 1996; 220: 5-8
13. Ferraro L, Antonelli T, O'Connor WT, et al. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry 1997; 42: 1181-3
14. Ferraro L, Fuxe K, Tanganelli S, et al. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J Neurosci Res 2002 Apr 1; 68 (1): 107-12
15. Ferraro L, Fuxe K, Tanganelli S, et al. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology 2000 Aug 23; 39 (11): 1974-83
16. de Saint Hilaire Z, Orosco M, Rouch C, et al. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport 2001 Nov 16; 12 (16): 3533-7
17. Ishizuka T, Sakamoto Y, Sakurai T, et al. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 2003 Mar 20; 339 (2): 143-6
18. Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001; 21 (5): 1787-94
19. De Séréville JE, Boer C, Rambert FA, et al. Lack of pre-synaptic dopaminergic involvement in modafinil activity in anaethetized mice: in vivo voltammetry studies. Neuropharmacology 1994; 33 (6): 755-61
20. Lin JS, Roussel B, Akaoka H, et al. Role of catecholamines in the modafanil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res 1992; 591: 319-26
21. 1- adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol 1990; 180: 49-58
22. Simon P, Hémet C, Ramassamy C, et al. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol 1995; 5: 509-14
23. Gallopin T, Luppi PH, Rambert FA, et al. Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 2004 Feb 1; 27 (1): 19-25
24. Hermant J-F, Rambert FA, Duteil J. Awakening properties of modafinil: effect on nocturnal activity in monkeys (Macaca mulatta) after acute and repeated administration. Psychopharmacology (Berl) 1991; 103: 28-32
25. Fuxe K, Janson AM, Rosén L, et al. Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis. Exp Brain Res 1992; 88: 117-30
26. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 1997; 283 (2): 757-69
27. Hou Y-P, Lin J-S. Effects of modafinil and amphetamine on sleep-wake cycle after sleep deprivation in cats. Acta Pharmacol Sin 1999 Sep; 20 (9): 813-8
28. Kopp C, Petit J-M, Magistretti P, et al. Comparison of the effects of modafinil and sleep deprivation on sleep and cortical EEG spectra in mice. Neuropharmacology 2002 Jul; 43 (1): 110-8
29. Lagarde D. Effects of modafinil on the nocturnal activity and behavioural sleep of Rhesus monkeys (Maccaca mulatta). Med Sci Res 1990; 18: 397-9
30. Lagarde D, Milhaud C. Electroencephalographic effects of modafinil, an alpha-1-adrenergic psychostimulant, on the sleep of Rhesus monkeys. Sleep 1990 Oct; 13 (5): 441-8
31. Lin JS, Gervasoni D, Hou Y, et al. Effects of amphetamine and modafinil on the sleep/wake cycle during experimental hypersomnia induced by sleep deprivation in the cat. J Sleep Res 2000 Mar; 9 (1): 89-96
32. Shelton J, Nishino S, Vaught J, et al. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995; 18 (10): 817-26
33. Touret M, Sallanon-Moulin M, Jouvet M. Awakening properties of modafinil without paradoxical sleep rebound: comparative study with amphetamine in the rat. Neurosci Lett 1995 Apr; 189: 43-6
34. Panckeri KA, Schotland HM, Pack AI, et al. Modafinil decreases hypersomnolence in the English bulldog, a natural animal model of sleep-disordered breathing. Sleep 1996; 19 (8): 626-31
35. Simon P, Hémet C, Costentin J. Analysis of stimulant locomotor effects of modafinil in various strains of mice and rats. Fundam Clin Pharmacol 1996; 10: 431-5
36. Randall DC, Shneerson JM, Plaha KK, et al. Modafinil affects mood, but not cognitive function, in healthy young volunteers. Hum Psychopharmacol 2003 Apr; 18 (3): 163-73
37. Saletu B, Frey R, Krupka M, et al. Differential effects of a new central adrenergic agonist - modafinil - and d-amphetamine on sleep and early morning behaviour in young healthy volunteers. Int J Clin Pharm Res 1989; 9 (3): 183-95
38. Saletu B, Frey R, Krupka M, et al. Differential effects of the new central adrenergic agonist modafinil and d-amphetamine on sleep and early morning behaviour in elderlies. Arzneimittel Forshung 1989 Oct; 39: 1268-73
39. Turner DC, Robbins TW, Clark L, et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 2003 Jan; 165 (3): 260-9
40. Baranski JV, Pigeau R, Dinich P, et al. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol 2004; 19: 323-32
41. Müller U, Steffenhagen N, Regenthal R, et al. Effects of modafinil on working memory processes in humans. Psychopharmacology (Berl) 2004; 177: 161-9
42. Bensimon G, Benoit D, Lacomblez L, et al. Antagonism by modafinil of the psychomotor and cognitive impairment induced by sleep-deprivation in 12 healthy volunteers. Eur Psychiatry 1991; 6: 93-7
43. Buguet A, Montmayeur A, Pigeau R, et al. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. II. Effects on two nights of recovery sleep. J Sleep Res 1995; 4: 229-41
44. Chapotot F, Pigeau R, Canini F, et al. Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG. Psychopharmacology (Berl) 2003 Mar; 166 (2): 127-38
45. Lagarde D, Batejat D, Van Beers P, et al. Interest of modafinil, a new psychostimulant, during a sixty-hour sleep deprivation experiment. Fundam Clin Pharmacol 1995; 9: 271-9
46. Pigeau R, Naitoh P, Buguet A, et al. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res 1995; 4: 212-28
47. Stivalet P, Esquivié D, Barraud P-A, et al. Effects of modafinil on attentional processes during 60 hours of sleep deprivation. Hum Psychopharmacol 1998 Oct; 13: 501-7
48. Wesensten NJ, Belenky G, Kautz MA, et al. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology (Berl) 2002 Jan; 159 (3): 238-47
49. Hughes RJ, Van Dongen H, Dinges DF, et al. Modafinil improves alertness and performance during simulated night work [abstract no. 336.E]. Sleep 2001 Apr 15; 24 Suppl.: A200
50. Walsh JK, Randazzo AC, Stone KL, et al. Modafinil improves alertness, vigilance, and executive function during simulated night shifts. Sleep 2004; 27 (3): 434-9
51. Sackner-Bernstein J, Arora S, Earl CQ. Safety of the centrally acting wake-promoting agent modafinil in hypertensive sleep apnea patients [abstract no. 1203-129]. J Am Coll Cardiol 2003 Mar 19; 41 (6 Suppl. A): 310-1
52. Kingshott RN, Vennelle M, Coleman EL, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 2001 Mar; 163 (4): 918-23
53. Pack AI, Black JE, Schwartz JR, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001 Nov 1; 164 (9): 1675-81
54. Brun J, Chamba G, Khalfallah Y, et al. Effect of modafinil on plasma melatonin, cortisol and growth hormone rhythms, rectal temperature and performance in healthy subjects during a 36 h sleep deprivation. J Sleep Res 1998 Jun; 7 (2): 105-14
55. Launay J-C, Besnard Y, Guinet A, et al. Effects of modafinil on heat thermoregulatory responses in humans at rest. Can J Physiol Pharmacol 2002 Aug; 80 (8): 796-803
56. Jasinski DR, Kovačević-Ristanović R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 2000; 23 (3): 149-56
57. Warot D, Corruble E, Payan C, et al. Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine and placebo. Eur Psychiatry 1993; 8: 201-8
58. Rush CR, Kelly TH, Hays LR, et al. Acute behavioral and physiological effects of modafinil in drug abusers. Behav Pharmacol 2002 Mar; 13 (2): 105-15
59. Rush CR, Kelly TH, Hays LR, et al. Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend 2002 Aug 1; 67 (3): 311-22
60. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol (Oxf) 2000; 14 (1): 53-60
61. Myrick H, Malcolm R, Taylor B, et al. Modafinil: preclinical, clinical, and post-marketing surveillance - a review of abuse liability issues. Ann Clin Psychiatry 2004; 16: 101-9
62. Cephalon UK Limited . Provigil 100mg tablets, Provigil 200mg tablets: prescribing information [online]. Available from URL: http://emc.medicines.org. uk [Accessed 2004 Apr 29]
63. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42 (2): 123-37
64. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999 Mar; 39 (3): 281-8
65. Moachon G, Matinier D, Lubin S, et al. Pharmacokinetics of multiple doses of modafinil in hepatic insufficiency [abstract no. P12.2.36]. Can J Physiol Pharmacol 1994; 72 Suppl. 1: 303
66. Robertson P, DeCory HH, Madan A, et al. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 2000 Jun; 28 (6): 664-71
67. Robertson P Jr, Hellriegel ET, Arora S, et al. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol 2002 Feb; 42 (2): 205-14
68. Robertson P Jr, Hellriegel ET, Arora S, et al. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther 2002 Jan; 71 (1): 46-56
69. Hellriegel ET, Arora S, Nelson M, et al. Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers. J Clin Pharmacol 2002 Apr; 42 (4): 450-60
70. Hellriegel ET, Arora S, Nelson M, et al. Steady-state pharmacokinetics and tolerability of modafinil given alone or in combination with methylphenidate in healthy volunteers. J Clin Pharmacol 2001 Aug; 41 (8): 895-904
71. Wong YN, Wang L, Hartman L, et al. Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers. J Clin Pharmacol 1998 Oct; 38 (10): 971-8
72. Wong YN, King SP, Laughton WB, et al. Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol 1998 Mar; 38 (3): 276-82
73. Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 2005; 28 (4): 464-71
74. Dinges DF, Weaver TE. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Med 2003 Sep; 4 (5): 393-402
75. Black J, Hirshkowitz M, Earl CQ. Modafinil adjunctive therapy improves excessive sleepiness and quality of life in obstructive sleep apnea: a 12-month open-label extension study [abstract no. 0680.J]. Sleep 2003; 26 Suppl.: A270
76. Schwartz JRL, Hirshkowitz M, Erman MK, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest 2003 Dec; 124 (6): 2192-9
77. Czeisler CA, Walsh JK, Roth T, et al. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med 2005 Aug 4; 353 (5): 476-86
78. Rosenberg R, Erman M, Emsellem H, et al. Modafinil improves quality of life and is well tolerated in shift work sleep disorder [abstract no. 0278.E]. Sleep 2003; 26 Suppl.: A112-113
79. Rosenberg R, Corser B. Patient functional status, safety, and tolerability of modafinil in a 12-month open-label study in patients with chronic shift work sleep disorder [abstract no. 129]. Sleep 2004 Jun 5; 27 Suppl.: A57-8
80. Erman MK, Dinges DF, Czeisler CA, et al. Patient functional status and tolerability of long-term modafinil in shift work sleep disorder [abstract no. 127]. Sleep 2004 Jun 5; 27 Suppl.: A56-7
81. Douglas NJ. Why am I sleepy? Sorting the somnolent. Am J Respir Crit Care Med 2001; 163: 1310-3
82. Pack AI. Should a pharmaceutical be approved for the broad indication of excessive sleepiness? Am J Respir Crit Care Med 2003 Jan 15; 167 (2): 109-11
83. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993 Apr 29; 328 (17): 1230-5
84. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnoea: a population health perspective. Am J Respir Crit Care Med 2002; 165: 1217-39
85. Gami AS, Howard DE, Olson EJ. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med 2005 Mar 24; 352 (12): 1206-14
86. Malhorta A, White DP. Obstructive sleep apnoea. Lancet 2002 Jul 20; 360: 237-45
87. Black J. Modafinil and sleepiness [letter]. Am J Respir Crit Care Med 2003 Dec 15; 168 (12): 1538-9
88. Pollak CP. Con: modafinil has no role in management of sleep apnea. Am J Respir Crit Care Med 2003 Jan 15; 167 (2): 106-7
89. Douglas NJ. Modafinil and sleepiness [letter]. Am J Respir Crit Care Med 2003 Dec 15; 168 (12): 1538
90. Ohayon MM, Lemoine P, Arnaud-Briant V, et al. Prevalence and consequences of sleep disorders in a shift worker population. J Psychosom Res 2002; 53 (1): 577-83
91. Beers TM. Flexible schedules and shift work: replacing the '9-to-5' workday? Mon Labor Rev 2000 Jun; 123 (6): 33-40
92. Härmä M, Sallinen M, Ranta R, et al. The effect of an irregular shift system on sleepiness at work in train drivers and railway traffic controllers. J Sleep Res 2002; 11 (2): 141-51
93. Gold DR, Rogacz S, Bock N, et al. Rotating shift work, sleep, and accidents related to sleepiness in hospital nurses. Am J Public Health 1992 Jul; 82 (7): 1011-4
94. Richardson GS, Miner JD, Czeisler CA. Impaired driving performance in shiftworkers: the role of the circadian system in a multifactorial model. Alcohol Drugs Driving 1989; 5/6 (4/1): 265-73
95. Dawson D, Cambell SS. Timed exposure to bright light improves sleep and alertness during simulated night shifts. Sleep 1991; 14 (6): 511-6
96. Eastman CI, Boulos Z, Terman M, et al. Light treatment for sleep disorders: consensus report. J Biol Rhythms 1995 Jun; 10 (2): 157-64
97. Czeisler CA, Johnson MP, Duffy JF, et al. Exposure of bright light and darkness to treat physiologic maladaptation to night work. N Engl J Med 1990 May 3; 322 (18): 1253-9
98. Muehlbach MJ, Walsh JK. The effects of caffeine on simulated night-shift work and subsequent daytime sleep. Sleep 1995; 18 (1): 22-9
99. Walsh JK, Muehlbach MJ, Humm TM, et al. Effect of caffeine on physiological sleep tendency and ability to sustain wakefulness at night. Psychopharmacology (Berl) 1990; 101 (2): 271-3
100. Walsh JK, Schweitzer PK, Anch AM, et al. Sleepiness/alertness on a simulated night shift following sleep at home with triazolam. Sleep 1991 Apr; 14 (2): 140-6
101. Porcù S, Bellatreccia A, Ferrara M, et al. Performance, ability to stay awake, and tendency to fall asleep during the night after a diurnal sleep with temazepam or placebo. Sleep 1997; 20 (7): 535-41
102. Hart CL, Ward AS, Haney M, et al. Methamphetamine attenuates disruptions in performance and mood during simulated night-shift work. Psychopharmacology (Berl) 2003; 169: 42-51
103. Sharkey KM, Eastman CI. Melatonin phase shifts human circadian rhythms in a placebo-controlled simulated night-work study. Am J Physiol Regulatory Integrative Comp Physiol 2002; 282: R454-63
104. Wright SW, Lawrence LM, Wrenn KD, et al. Randomized clinical trial of melatonin after night-shift work: efficacy and neuropsychologic effects. Ann Emerg Med 1998 Sep; 32 (3 Pt 1): 334-40
105. Jockovich M, Cosentino D, Cosentino L, et al. Effect of exogenous melatonin on mood and sleep efficiency in emergency medicine residents working night shifts. Acad Emerg Med 2000 Aug; 7 (8): 955-8
106. Sallinen M, Härmä M, Akerstedt T, et al. Promoting alertness with a short nap during a night shift. J Sleep Res 1998; 7: 240-7
107. Schwartz JRL. Pharmacologic management of daytime sleepiness. J Clin Psychiatry 2004; 65 Suppl. 16: 46-9
108. Guilleminault C, Philip P. Tiredness and somnolence despite initial treatment of obstructive sleep apnea syndrome (what to do when an OSAS patient stays hypersomnolent despite treatment). Sleep 1996; 19 Suppl. 9: S117-22
109. Smith IE, Quinnell TG. Pharmacotherapies for obstructive sleep apnoea: where are we now? Drugs 2004; 64 (13): 1385-99
110. Nicholson AN, Turner C. Intensive and sustained air operations: potential use of the stimulant pemoline. Aviat Space Environ Med 1998 Jul; 69 (7): 647-55
111. Besset A, Chetrit M, Carlander B, et al. Use of modafinil in the treatment of narcolepsy: a longer term follow-up study. Neurophysiol Clin 1996; 26: 60-6
112. Happe S. Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management. Drugs 2003; 63 (24): 2725-37